6 registrations that name saccharomyces boulardii as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 6 registrations
Status
Phase
All 6 registrations
RecruitingNCT07139366
Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment
Phase 4
Yongquan Shi
About 1,248 people
Started Oct 28, 2025
In plain words A Phase 4 study of saccharomyces boulardii in people 18 to 75, run by Yongquan Shi. It plans to enroll about 1,248 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Gastritis; Dyspepsia; Helicobacter Pylori Infection; Gastric Cancer; Peptic Ulcer.
Age between 18~75, both gender.
Patients who had failed H.pylori eradication therapies .
Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.
This study aims at evaluating efficacy and safety of Saccharomyces boulardii combined with bismuth-containing quadruple Therapy versus bismuth-containing quadruple Therapy(bismuth#esomeprazole#tetracycline and furazolidone) in H. pylori rescue therapy. It is hypothesized that Saccharomyces boulardii combined with bismuth-containing quadruple Therapy is superior to bismuth-containing quadruple Therapy. Patients with confirmed failure of H. pylori eradication will be randomized to one of the treatments described above. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07168434
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
Phase 3
Biocodex
About 406 people
Started Oct 22, 2025
In plain words A Phase 3 study of saccharomyces boulardii in people 18 to 65, run by Biocodex. It plans to enroll about 406 people at 10 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: IBS (Irritable Bowel Syndrome); IBS-D (Diarrhea-predominant); IBS, Mixed Symptoms.
Male or female aged ≥ 18 and ≤ 65 years.
Diagnosis of IBS of any subtype, except constipation predominant (IBS-C), according to Rome IV criteria.
IBS-SSS total score ≥ 175 at inclusion.
Able and willing to maintain their nutrition habits throughout the study participation.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Saccharomyces Boulardii 250 MG; Placebo 250 mg
Registered summary
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global IBS symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks. The full summary is on the listing.
Where, as registered
No US site; Spain (8), Portugal (2).
Not yet recruitingNCT07815548
Comparison of the Efficacy of Saccharomyces Boulardii and Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth
Phase 4
Shandong University
About 222 people
Starts Sep 10, 2026 (estimated)
In plain words A Phase 4 study of saccharomyces boulardii in people 18 to 70, run by Shandong University. It plans to enroll about 222 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Small Intestinal Bacterial Overgrowth Syndrome (SIBO).
Aged between 18 and 70 years, male or female.
Presenting with chief complaints of abdominal distension and/or diarrhea.
Diagnosis of small intestinal bacterial overgrowth (SIBO) confirmed by positive hydrogen-methane breath test.
This multicenter randomized controlled study aims to systematically evaluate the efficacy and safety of Saccharomyces boulardii sachets versus rifaximin in the treatment of small intestinal bacterial overgrowth (SIBO), with a focus on symptom relief and the impacts of anxiety-depressive factors on the treatment of abdominal distension and diarrhea in SIBO patients. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07012785
Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection
No phase
Zhongda Hospital
About 208 people
Starts Jun 2025 (estimated)
In plain words A study of saccharomyces boulardii in people 18 to 70, run by Zhongda Hospital. It plans to enroll about 208 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: H. Pylori Infection.
Aged 18-70 years, regardless of gender;
Positive 13C/14C urea breath test result;
No previous history of H. pylori eradication treatment;
Agreement to participate in this study and signing of the informed consent form.
To assess the efficacy and safety of Saccharomyces boulardii combined with triple therapy containing minocycline in the initial eradication of Helicobacter pylori (H. pylori) infection
Where, as registered
No US site; China (1).
Not yet recruitingNCT07813182
Efficacy and Safety of Saccharomyces Boulardii in Treatment of Acute Diarrhea in Children Aged 6 Months to 5 Years Old
No phase
Can Tho University of Medicine and Pharmacy
About 206 people
Starts Aug 31, 2026 (estimated)
In plain words A study of saccharomyces boulardii in people 6 months to 60 months, run by Can Tho University of Medicine and Pharmacy. It plans to enroll about 206 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 months to 60 months; healthy volunteers accepted. Conditions: Acute Diarrhea.
Age from 6 months to 5 years old
Children are diagnosed with acute diarrhea according to WHO criteria.
The exclusion criteria are on the listing.
What it tests, as registered
Saccharomyces Boulardii Probiotic Supplement; The child will be treated with standard method
Registered summary
This study aimed to evaluate the effectiveness of saccharomyces-based treatment in children with acute diarrhea aged 6 months to 5 years compared to children treated with standard methods.
Where, as registered
No US site; Vietnam (1).
Not yet recruitingNCT07785206
Effectiveness of Saccharomyces Boulardii in Prevention of Antibiotic Associated Diarrhea
No phase
University of Child Health Sciences and Children's Hospital, Lahore
About 88 people
Starts Sep 2026 (estimated)
In plain words A study of saccharomyces boulardii in people 6 months to 5, run by University of Child Health Sciences and Children's Hospital, Lahore. It plans to enroll about 88 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 months to 5. Conditions: Antibiotic Associated Diarrhea; Upper Respiratory Tract Infection.
Children aged 6 months to 5 years presenting with upper respiratory tract infection (URTI)
Prescribed standard oral co-amoxiclav therapy
Both male and female patients
Written informed consent provided by parents or legal guardians
The exclusion criteria are on the listing.
What it tests, as registered
Co-amoxiclav; Saccharomyces boulardii
Registered summary
Antibiotic-associated diarrhea (AAD) is a common adverse effect in pediatric patients receiving broad-spectrum antibiotics such as co-amoxiclav for upper respiratory tract infections (URTI). This study aims to evaluate the effectiveness of the probiotic Saccharomyces boulardii in preventing antibiotic-associated diarrhea among children aged 6 months to 5 years receiving co-amoxiclav. Participants will be randomly allocated to receive either standard co-amoxiclav therapy alone or co-amoxiclav combined with Saccharomyces boulardii for 5 days. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
ClinicalTrials.gov lists 11 open registrations for this search, including ones where saccharomyces boulardii is not a study arm or that are past the 6 we keep. Search them on ClinicalTrials.gov (opens in new tab).